Shared on 27 Oct 25
Analysts have maintained ANGLE's fair value estimate at $0.11 per share. Their outlook remains steady after a review of updated company fundamentals and underlying discount rates.
Shared on 13 Oct 25
Fair value Decreased 38%Analysts have lowered their price target for ANGLE from $0.17 to $0.105. They cite updated projections of higher revenue growth, but reduced profit margins and a higher discount rate are impacting the company's fair value assessment.
Shared on 11 Sep 25
Fair value Decreased 39%Despite a substantial increase in consensus revenue growth forecasts, ANGLE’s future P/E multiple has halved, reflecting a notable de-rating and driving the fair value estimate down from £0.28 to £0.17. What's in the News ANGLE plc announced a collaboration with Myriad Genetics, utilising ANGLE's Parsortix system to process cancer patient blood samples for molecular analysis, comparing CTC-DNA with matched tissue samples via Myriad's assay; further details remain confidential.